BRAIN Biotech AG (FRA:BNN)

Market Cap	62.27M +47.3%
Revenue (ttm)	48.31M -9.7%
Net Income	-11.02M
EPS	-0.51
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54
Open	3.000
Previous Close	2.760
Day's Range	2.850 - 3.000
52-Week Range	1.860 - 3.810
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About BRAIN Biotech AG

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 280
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BNN

Financial Performance

In fiscal year 2025, BRAIN Biotech AG's revenue was 50.22 million, a decrease of -9.52% compared to the previous year's 55.50 million. Losses were -11.74 million, 5.53% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 20, 2026

Data Sources Report a data error